Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and purported market share. However, beginning on April 25, 2024, DexCom made its first in a series of public corrective disclosures announcing that the company's growth and business prospects were far lower than it had previously claimed. By the time the company made its final corrective disclosure on July 25, 2024, the price of DexCom's shares had plummeted by over 40.6%.
Current stockholders who held their DexCom stock before April 28, 2023, are encouraged to contact Johnson Fistel to discuss their legal rights in this matter. You can click or copy and paste the following link to join this investigation: https://www.johnsonfistel.com/investigations/dexcom-inc-2
About Johnson Fistel, PLLP:
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 days ago
- Business Wire
Johnson Fistel Launches Probe into Skechers Go Private Deal
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading shareholder rights law firm, has commenced an investigation into whether the board of directors of Skechers U.S.A., Inc. (NYSE: SKX) breached its fiduciary duties in connection with the proposed sale of the Company to 3G Capital Corp. ('3G'). The inquiry focuses on the fairness of the consideration being offered to Skechers' public shareholders and whether the transaction reflects full and fair value for all shareholders. Over the twelve months preceding the announcement of the deal, Skechers common stock traded at levels approaching $80.00 per share, raising potential concerns Share On May 5, 2025, Skechers entered into a definitive agreement under which 3G will acquire all outstanding shares of common stock in a go-private transaction. Under the terms of the agreement, each holder of Skechers common stock may elect to receive either: • $63.00 in cash per share, or • $57.00 in cash per share plus one unit in the post-closing private entity controlled by 3G. Over the twelve-month period preceding the announcement of the deal, Skechers common stock traded at levels approaching $80.00 per share, raising potential concerns that the proposed cash consideration and equity rollover option may undervalue shareholder interests. Johnson Fistel's investigation will examine, among other issues: • Whether Skechers' board of directors satisfied its fiduciary duty to secure the highest attainable cash consideration for public shareholders; • The process by which the board evaluated strategic alternatives and negotiated deal terms; • The adequacy of the disclosure provided to investors regarding the proposed go-private transaction; and • Any conflicts of interest that may have influenced the board's recommendation. You can click or copy and paste the following link to join this investigation: If you are a shareholder of Skechers and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb@ at 619-814-4471. If emailing, please include a phone number. About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, PLLP can help you recover your losses. For more information about the firm and its attorneys, please visit Achievements: In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs' securities law firm in the United States, as determined by the total dollar value of final recoveries. Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Yahoo
5 days ago
- Yahoo
Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth
-- Truist Securities launched coverage on four diabetes technology companies, saying there is a long-term growth potential for continuous glucose monitors (CGM) and insulin pumps amid rising adoption in both type 1 and type 2 diabetes patients. The firm started Dexcom (NASDAQ:DXCM), Insulet (NASDAQ:PODD), and Beta Bionics with Buy ratings, while initiating Tandem Diabetes Care (NASDAQ:TNDM) at Hold. Truist already covers Medtronic's diabetes business, which it rates 'Hold.' Truist said the diabetes device sector is positioned for double-digit growth over the next several years, driven by expanding use in underpenetrated global markets and a shift toward more patient-centric care. Survey feedback from physicians suggested stronger adoption of pumps and CGMs in type 2 diabetes, particularly among patients using insulin. Among the large-cap names, the firm favored Dexcom and Insulet, citing strong profitability and leadership in the growing CGM and patch pump segments. While Truist said that Insulet's recent CEO change may introduce some near-term uncertainty, it said the company's growth trajectory remains intact. Dexcom, which has faced concerns following mid-2024 execution missteps and rising competition from Abbott's Libre system, still offers a favorable risk-reward, Truist said, pointing to a lower relative valuation and catalysts such as guideline updates and expanding reimbursement for type 2 diabetes. In the small-cap space, Truist preferred Beta Bionics over Tandem. It noted both firms face challenges in the slower-growing durable pump market but said Beta Bionics' iLet system has a potential ease-of-use advantage and a head start in transitioning to more profitable pharmacy distribution channels. Regarding potential volatility in shares of both Beta Bionics and Tandem, Truist said the broader diabetes device market remains one of the most attractive growth areas in medtech, supported by technology innovation, evolving reimbursement, and increased patient engagement. Related articles Truist starts on diabetes device makers, sees glucose monitor, insulin pump growth Boeing Commercial Airplanes head meets Air India chairman after fatal 787 crash Forward Air stock surges on report PE firms express acquisition interest
Associated Press
11-06-2025
- Associated Press
Iovance Biotherapeutics Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) SAN DIEGO, CA, UNITED STATES, June 11, 2025 / / -- Shareholder rights law firm Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). If you incurred significant losses and want to act as the lead plaintiff in the class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here: CLASS PERIOD: May 9, 2024, through May 8, 2025 LEAD PLAINTIFF DEADLINE: July 14, 2025 DOCKET #: 25-CV-04177 (N.D. California) ALLEGATIONS: False and/or misleading statements Contact for More Information: James Baker, (619) 814-4471, [email protected] or [email protected] The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about Iovance's business, operations, and prospects, including allegations that: (1) new Authorized Treatment Centers ('ATCs') were experiencing longer timelines to begin treating patients with Amtagvi; (2) Iovance's sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs; and (3) the foregoing dynamics led to higher costs and lower revenue because ATCs could not keep pace with manufactured product. If you purchased shares and experienced losses, and would like to learn more about serving as lead plaintiff, please contact Jim Baker at 619-814-4471 or [email protected]. Please include your name and contact information. To learn more about the lead plaintiff process, visit: About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Colorado, and Idaho. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, PLLP can help you recover your losses. For more information about the firm and its attorneys, please visit Achievements: In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs' securities law firm in the United States, as determined by the total dollar value of final recoveries. Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content. Contact: Johnson Fistel, PLLP 501 W. Broadway, Suite 800, San Diego, CA 92101 James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471 [email protected] or [email protected] Johnson Fistel, PLLP Johnson Fistel +1 619-814-4471 email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
